# Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder

> **NCT02909959** · PHASE2 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 48 (actual)

## Conditions studied

- Autism Spectrum Disorder
- Autistic Disorder
- Neurodevelopmental Disorder
- Childhood Developmental Disorders, Pervasive

## Interventions

- **DRUG:** Sulforaphane
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02909959
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2019-05-30
- **Final completion:** 2019-05-30
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02909959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02909959, "Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02909959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*